» Articles » PMID: 35144440

Ototoxicity Monitoring in South African Cancer Facilities: A National Survey

Overview
Date 2022 Feb 11
PMID 35144440
Authors
Affiliations
Soon will be listed here.
Abstract

Background: National information regarding ototoxicity monitoring practices are limited for patients undergoing chemotherapy in South Africa.

Objectives: To determine (1) the national status of ototoxicity monitoring implemented in private and public cancer facilities, (2) the knowledge and ototoxicity monitoring approaches implemented, and (3) reported challenges.

Method: A descriptive quantitative survey was conducted in public and private oncology units and audiology referral clinics. Private (60%) and public (43%) oncology units that provide platinum-based chemotherapy in South Africa and audiology referral units (54%) were: (1) surveyed telephonically to determine if ototoxicity monitoring takes place; and (2) a self-administered survey was sent to qualifying oncology units and audiology referral clinics.

Results: All public oncology units reported that ototoxicity monitoring only occurs on referral and is not standard practice. All private oncology units indicated that monitoring is on a patient self-referral basis when symptoms occur. Poor awareness of ototoxicity monitoring best practice guidelines was reported by all oncology units and 14% of audiology referral clinics. Audiology referral clinics reported adequate knowledge of ototoxicity protocols although they are not widely used with only 43% following best practice guidelines. The most prominent challenges reported by participants was referral system (67% oncology units; 57% audiology referral clinics), environmental noise (83% oncology units; 86% audiology referral clinics) and the compromised status of cancer patients (67% oncology units; 57% audiology referral clinics).

Conclusion: Ototoxicity monitoring is not routinely implemented across oncology units in South Africa. Multidisciplinary teamwork and a simplified national ototoxicity monitoring protocol may improve hearing outcomes for patients.

Citing Articles

Healthcare professionals' knowledge and practices in managing ototoxicity in children with cancer.

Ramnarian K, Paken J S Afr J Commun Disord. 2024; 71(1):e1-e15.

PMID: 39625086 PMC: 11622129. DOI: 10.4102/sajcd.v71i1.1064.


Roadmap to a Global Template for Implementation of Ototoxicity Management for Cancer Treatment.

Fernandez K, Hoetink A, Konrad-Martin D, Berndtson D, Clark K, Dreisbach L Ear Hear. 2024; 46(2):286-297.

PMID: 39261989 PMC: 11832334. DOI: 10.1097/AUD.0000000000001592.


Trends in ototoxicity monitoring among cisplatin-treated patients with cancer.

Lee D, Travis E, Wong S, Munyemana M, Mueller L, Rowling C J Cancer Surviv. 2024; .

PMID: 38630333 DOI: 10.1007/s11764-024-01586-3.

References
1.
Wildes T, Dua P, Fowler S, Miller J, Carpenter C, Avidan M . Systematic review of falls in older adults with cancer. J Geriatr Oncol. 2014; 6(1):70-83. PMC: 4297689. DOI: 10.1016/j.jgo.2014.10.003. View

2.
Whitehorn H, Sibanda M, Lacerda M, Spracklen T, Ramma L, Dalvie S . High prevalence of cisplatin-induced ototoxicity in Cape Town, South Africa. S Afr Med J. 2014; 104(4):288-91. DOI: 10.7196/samj.7389. View

3.
Ganesan P, Schmiedge J, Manchaiah V, Swapna S, Dhandayutham S, Kothandaraman P . Ototoxicity: A Challenge in Diagnosis and Treatment. J Audiol Otol. 2018; 22(2):59-68. PMC: 5894487. DOI: 10.7874/jao.2017.00360. View

4.
Yousuf Hussein S, Swanepoel D, Biagio de Jager L, Myburgh H, Eikelboom R, Hugo J . Smartphone hearing screening in mHealth assisted community-based primary care. J Telemed Telecare. 2015; 22(7):405-12. DOI: 10.1177/1357633X15610721. View

5.
Oun R, Moussa Y, Wheate N . The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018; 47(19):6645-6653. DOI: 10.1039/c8dt00838h. View